Advancing Technologies to Improve Delivery of Pharmacological, Gene Editing, and other Cargoes for HIV and SUD Mechanistic or Therapeutic Research (R01 Clinical Trial Optional)
ID: 350820Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/350820

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-022.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Technologies to Improve Delivery of Pharmacological, Gene Editing, and other Cargoes for HIV and SUD Mechanistic or Therapeutic Research (R01 Clinical Trial Optional)." This initiative aims to support the development of innovative technologies that enhance the delivery of treatment agents for HIV and substance use disorders (SUD), particularly focusing on preclinical research targeting HIV reservoirs in the central nervous system. The program encourages diverse and inclusive research approaches, requiring applicants to submit a Plan for Enhancing Diverse Perspectives (PEDP) as part of their proposals. A total funding of $2 million is anticipated for four to six projects in fiscal year 2025, with applications due by November 15, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-022.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-DA-25-022-Full-Announcement.html
    RFA-DA-25-022.html
    The Department of Health and Human Services is issuing a funding opportunity aimed at advancing technologies for delivering pharmacological and gene editing interventions for HIV and substance use disorders (SUD). This initiative, led by the National Institute on Drug Abuse, invites applications under the R01 Research Project Grant mechanism. The key objective is to drive preclinical research that explores novel methods for targeted delivery of treatment agents to HIV reservoirs, particularly in the central nervous system, and to address the challenges faced by individuals with SUD. Applicants must include a Plan for Enhancing Diverse Perspectives (PEDP) focused on inclusivity in the research context. The funding opportunity details the application timeline, including submission deadlines and review processes. It encourages innovative approaches that can significantly contribute to understanding HIV and SUD, urging researchers to develop technologies with measurable and timely milestones. Eligibility extends to various organizations, including educational institutions and non-profits, promoting collaboration across diverse fields. A total funding of $2 million is anticipated for four to six projects in fiscal year 2025, reflecting the government's commitment to tackle pressing health challenges through innovative research.
    Similar Opportunities
    Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders" through the R01 Research Project Grant. This initiative aims to support innovative and high-risk studies that explore the molecular mechanisms linking HIV and substance use disorders (SUDs), with a focus on advancing understanding of HIV dynamics within the Central Nervous System (CNS). The total estimated program funding is $2 million for fiscal year 2026, with the potential to support up to three awards, and applications must include clear milestones and human or primate studies. Interested applicants should note that the deadline for submitting letters of intent and applications is July 14, 2025, and no clinical trials are permitted under this grant. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for exploratory studies focused on the mechanisms of HIV infection, replication, latency, and pathogenesis in the context of substance use disorders (SUDs). This initiative aims to support high-risk, high-impact research that utilizes innovative tools to investigate the interactions between HIV and addictive substances, with a particular emphasis on understanding the molecular mechanisms involved and the effects of these substances on HIV latency and replication. The total funding budget for this opportunity is $2 million, intended to support three awards, each capped at $700,000 in direct costs annually. Applications are due by July 14, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. For more details, please refer to the full announcement available at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-011.html.
    High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)" aimed at supporting innovative research at the intersection of HIV and substance use. This initiative seeks proposals that address critical gaps in understanding and improving health outcomes for individuals living with HIV who also face substance use disorders, requiring detailed research plans and preliminary data from both individual researchers and research teams. NIH plans to allocate approximately $3 million annually for three to five awards over three years, with applications due by January 11, 2025, and a strong emphasis on enhancing diverse perspectives through an inclusion plan. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-024.html.
    Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity titled "Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed)." This initiative aims to investigate the protein interaction networks in HIV-infected microglia and their implications for cellular signaling alterations associated with the coexistence of HIV and SUD, structured in a two-phase approach focusing on both quantitative analytics and in vivo models. The funding, anticipated to be approximately $2.5 million for FY 2026, will support 3-6 awards, with applications opening on July 14, 2025, and a submission deadline of August 14, 2025. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Research on the Neuro-Immune Axis in the context of HIV and Substance Use," aimed at advancing the understanding of the interplay between neuroimmune networks and the effects of HIV and substance use disorders (SUD). This R01 Clinical Trial Not Allowed grant seeks applications that explore neuroimmune interactions, therapeutic targets, and modulatory tools, with a focus on examining the molecular mechanisms and regulatory pathways influenced by substance use in relation to HIV pathogenesis. The opportunity is significant for addressing HIV-related neurological issues exacerbated by substance abuse, with a total funding of up to $2 million projected for FY 2025 to support up to six projects. Interested applicants must submit their proposals by November 13, 2024, and can find additional information and application instructions at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" aimed at supporting innovative research that addresses the intersection of HIV and substance use. This initiative invites applications from individual researchers and research teams to develop projects that can lead to new prevention, treatment, and care strategies for individuals affected by both conditions, with a requirement for a detailed research plan and preliminary data. A total budget of $3.0 million is available for funding one to two awards, with individual project budgets capped at $1.5 million per fiscal year, and applications are due by February 12, 2027. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to consult with NIDA program staff early in the application process.
    Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)." This initiative aims to encourage research into the role of inflammasomes in the neuropathology associated with HIV infection and substance use disorders, particularly focusing on their impact on neurocognitive disorders and immune function. The program seeks to bridge knowledge gaps in treatment and research by exploring how inflammasome activation is influenced by HIV and substance use, with the goal of translating findings into clinical applications. A total funding amount of $2 million is available to support up to four grants, with a submission deadline of February 13, 2024. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Ex Vivo Models for Studies at the Intersection of HIV and Poly-Substance Use (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting grant applications for the initiative titled "Ex Vivo Models for Studies at the Intersection of HIV and Poly-Substance Use (R01 Clinical Trial Not Allowed)." This funding opportunity aims to investigate the neuroimmune and neuronal-glial mechanisms associated with HIV-associated neurological disorders (HAND) using advanced ex vivo culturing platforms derived from human induced pluripotent stem cells (hiPSC) in the context of addictive substances. The research is critical for understanding the genetic, epigenetic, and neuroimmune interactions that contribute to HAND, particularly in the presence of substances like opioids and cocaine. The NIH has committed a total of $2 million annually for Fiscal Years 2024-2026, with applications due by 5 PM local time on August 13, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV," aimed at exploring the interactions between HIV-infected microglia and substance use disorder. The objective is to generate specific microglial protein profiles and interaction networks to understand how these factors contribute to neuropathologies associated with both conditions, utilizing innovative protein profiling techniques across two study phases: R61 for analytical methods and R33 for in vivo models. This funding opportunity is significant for advancing research in health, with a total funding amount of $2.5 million available for 3-6 awards by fiscal year 2025. Interested applicants must submit their proposals by August 14, 2025, and can direct inquiries to grantsinfo@nih.gov for further information.
    Development and Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs (R34 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity (PA-21-205) aimed at the development and testing of innovative interventions to enhance HIV prevention, treatment, and program implementation for individuals who use drugs. This R34 grant focuses on formative research and pilot studies that assess the feasibility, safety, and acceptability of various interventions, including behavioral, social, and structural approaches, particularly integrating substance use considerations into HIV care. The initiative is crucial in addressing the ongoing challenges of the HIV epidemic among populations significantly impacted by substance use, with projects expected to enhance HIV testing, preventive services, and treatment adherence. Interested applicants can apply for grants with a ceiling of $225,000, and the application deadline is January 7, 2025. For further information, contact the NIH OER Webmaster at grantsinfo@nih.gov or visit the funding announcement at http://grants.nih.gov/grants/guide/pa-files/PA-21-205.html.